Purple Biotech (PPBT) Change in Receivables (2016 - 2026)
Purple Biotech (PPBT) reported Change in Receivables of -$2.1 million for Q1 2026, down 558.99% year-over-year from $456000.0 in Q1 2025, and down 108.85% quarter-over-quarter from $23.6 million in Q4 2025.
Purple Biotech (PPBT) Change in Receivables (2016 - 2026) Analysis & Trends
Purple Biotech (PPBT) has 11 years of Change in Receivables data on file, last reported at -$2.1 million in Q1 2026.
- Change in Receivables for Q1 2026 came in at -$2.1 million, down 558.99% year-over-year; the trailing twelve-month figure through Mar 2026 was $23.9 million (up 504.62% YoY), and the FY2025 annual result was $26.5 million, up 364.0% from the prior year.
- Change in Receivables retreated to -$2.1 million in Q1 2026 per PPBT's latest filing, from $23.6 million in the prior quarter.
- Over five years, Change in Receivables peaked at $23.6 million in Q4 2025 and troughed at -$7.0 million in Q1 2022.
- A 5-year average of $3.5 million and a median of $3.6 million in 2022 frame the typical range for Change in Receivables.
- The sharpest annual moves came in 2025 and 2026: Change in Receivables surged 5596.87% in 2025, then tumbled 558.99% in 2026.
- A 5-year view of Change in Receivables shows it stood at $6.0 million in 2022, then retreated by 19.59% to $4.9 million in 2023, then plunged by 91.46% to $415000.0 in 2024, then surged by 5596.87% to $23.6 million in 2025, then tumbled by 108.85% to -$2.1 million in 2026.
- Business Quant data shows PPBT's Change in Receivables at -$2.1 million in Q1 2026, $23.6 million in Q4 2025, and $1.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | 22,529.00 |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | -39.80 Mn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -4.08 Mn |
| 10 | Purple Biotech | 242.86 Mn | 236.43 Mn | - | -2.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.09 Mn |
| Mar 31, 2026 | -2.09 Mn |
| Dec 31, 2025 | 23.64 Mn |
| Dec 31, 2025 | 23.64 Mn |
| Sep 30, 2025 | 1.31 Mn |
| Sep 30, 2025 | 1.31 Mn |
| Jun 30, 2025 | 1.09 Mn |
| Jun 30, 2025 | 1.09 Mn |
| Mar 31, 2025 | 456,000.00 |
| Mar 31, 2025 | 456,000.00 |
| Dec 31, 2024 | 415,000.00 |
| Dec 31, 2024 | 415,000.00 |
| Sep 30, 2024 | 668,000.00 |
| Sep 30, 2024 | 668,000.00 |
| Jun 30, 2024 | 2.42 Mn |
| Jun 30, 2024 | 2.42 Mn |
| Mar 31, 2024 | 3.80 Mn |
| Mar 31, 2024 | 3.80 Mn |
| Dec 31, 2023 | 4.86 Mn |
| Dec 31, 2023 | 4.86 Mn |